1. Endoscopic and Clinical Variables That Predict Sustained Remission in Children With Ulcerative Colitis Treated With Infliximab 
Dan Turner, Anne M. Griffiths, Gigi Veerman, Jewel Johanns, Lakshmi Damaraju, Marion Blank, Jeffrey Hyams 
Clinical Gastroenterology and Hepatology 
Volume 11, Issue 11, Pages (November 2013)
DOI: /j.cgh
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1
Percentage of children in sustained steroid-free 1-year clinical remission, stratified by those achieving remission at week 8 by the PUCAI and MH.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

3. Figure 2
Week 8 PUCAI score predicts 1-year steroid-free sustained remission.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

4. Figure 3
ROC curve to reflect the ability of the PUCAI, sigmoidoscopy, and CRP at week 8 to predict sustained steroid-free remission defined by PGA (A) or PaGA (B). AUC, area under the curve.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

5. Figure 4
Concordance between the PUCAI with sigmoidoscopic scoring (A) and with the Mayo scores (B) of 51 children 8 weeks after 3-dose induction with infliximab.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

6. Figure 5
The cutoff values of the PUCAI that correspond best with remission (A) and response (B) defined by the Mayo score. AUROC, area under the ROC curve.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions